Amalgamated Bank grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 25.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,449 shares of the medical research company’s stock after buying an additional 1,933 shares during the quarter. Amalgamated Bank’s holdings in Charles River Laboratories International were worth $956,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in CRL. BlackRock Inc. raised its position in shares of Charles River Laboratories International by 12,573.1% during the 1st quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock worth $345,915,000 after buying an additional 3,815,298 shares in the last quarter. FMR LLC raised its position in shares of Charles River Laboratories International by 39.7% during the 1st quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock worth $223,806,000 after buying an additional 707,612 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in shares of Charles River Laboratories International during the 1st quarter worth about $39,355,000. Marshall Wace North America L.P. bought a new stake in shares of Charles River Laboratories International during the 1st quarter worth about $39,355,000. Finally, Morgan Stanley raised its position in shares of Charles River Laboratories International by 201.5% during the 1st quarter. Morgan Stanley now owns 617,761 shares of the medical research company’s stock worth $55,569,000 after buying an additional 412,894 shares in the last quarter. Institutional investors own 95.37% of the company’s stock.

In other Charles River Laboratories International news, Chairman James C. Foster sold 9,516 shares of the company’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $98.92, for a total transaction of $941,322.72. Following the transaction, the chairman now directly owns 361,171 shares in the company, valued at approximately $35,727,035.32. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director George Massaro sold 3,830 shares of the company’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $100.81, for a total transaction of $386,102.30. Following the transaction, the director now owns 18,731 shares in the company, valued at $1,888,272.11. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,880 shares of company stock worth $2,541,668. 2.20% of the stock is owned by corporate insiders.

A number of research firms have commented on CRL. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 price target on the stock in a research report on Thursday, August 10th. Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price target on the stock. Jefferies Group LLC restated a “buy” rating and set a $121.00 price target on shares of Charles River Laboratories International in a research report on Friday, June 30th. BidaskClub upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Finally, Credit Suisse Group restated a “neutral” rating and set a $95.00 price target (up from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. Six equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Charles River Laboratories International currently has an average rating of “Buy” and an average price target of $99.59.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/28/charles-river-laboratories-international-inc-crl-holdings-increased-by-amalgamated-bank.html.

Charles River Laboratories International, Inc. (NYSE:CRL) opened at 107.03 on Thursday. Charles River Laboratories International, Inc. has a 52 week low of $67.20 and a 52 week high of $109.59. The firm has a market cap of $5.09 billion, a PE ratio of 28.20 and a beta of 0.99. The stock has a 50 day moving average of $103.50 and a 200 day moving average of $95.67.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million for the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.20 EPS. Analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.